×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Arcturus Therapeutics Holdings Inc. (ARCT) NASDAQ

$31.35 0.14 (0.43%)

Market Cap: $840.54M

As of 05/24/24 10:12 AM EDT. Market open.

(ARCT)

Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ

$31.35
0.14 (0.43%)

Market Cap: $840.54M

As of 05/24/24 10:12 AM EDT. Market open.

Add to Portfolio

founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive ... read more

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
184
Address
.
PRICE CHART FOR ARCTURUS THERAPEUTICS HOLDINGS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$31.74
Previous Close
$31.21
Days Range
$30.69 - $32.48
52 week range
$17.52 - $43.81
Volume
26,170
Avg. Volume (30 days)
480,196
Market Cap
$840.54M
Dividend Yield
-
P/E
(7.83)
Shares Outstanding
26,931,826
Open
$31.74
Previous Close
$31.21
Days Range
$30.69 - $32.48
52 week range
$17.52 - $43.81
Volume
26,170
Avg. Volume (30 days)
480,196
Market Cap
$840.54M
Dividend Yield
-
P/E
(7.83)
Shares Outstanding
26,931,826
FINANCIAL STATEMENTS FOR ARCTURUS THERAPEUTICS HOLDINGS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR ARCTURUS THERAPEUTICS HOLDINGS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Chivukula PadChief Scientific Officer & COOMar 25, 2024 Sale$35.0217,435610,574473,448Mar 27, 2024, 04:15 PM
Chivukula PadChief Scientific Officer & COOMar 19, 2024 Sale$35.018,565299,839490,883Mar 21, 2024, 05:27 PM
Chivukula PadChief Scientific Officer & COONov 01, 2023 Sale$18.725,00093,602499,448Nov 03, 2023, 04:30 PM
Chivukula PadChief Scientific Officer & COOOct 02, 2023 Sale$25.615,000128,062504,448Oct 04, 2023, 04:06 PM
Chivukula PadChief Scientific Officer & COOSep 01, 2023 Sale$31.455,000157,263509,448Sep 05, 2023, 04:05 PM
SASSINE ANDYChief Financial OfficerAug 15, 2023 Option Exercise$17.371,22321,248270,526Aug 17, 2023, 05:00 PM
Chivukula PadChief Scientific Officer & COOAug 01, 2023 Sale$34.915,000174,550514,448Aug 03, 2023, 04:15 PM
Chivukula PadChief Scientific Officer & COOJul 14, 2023 Sale$35.0125,000875,250519,448Jul 18, 2023, 06:50 PM
Kummerfeld Keith CSee RemarksJul 14, 2023 Option Exercise$8.966,96862,4087,918Jul 18, 2023, 06:50 PM
Kummerfeld Keith CSee RemarksJul 14, 2023 Sale$35.006,968243,880950Jul 18, 2023, 06:50 PM
Chivukula PadChief Scientific Officer & COOJul 03, 2023 Sale$28.755,000143,750544,448Jul 07, 2023, 06:01 AM
Chivukula PadChief Scientific Officer & COOJun 01, 2023 Sale$27.165,000135,800549,448Jun 05, 2023, 04:07 PM
Chivukula PadChief Scientific Officer & COOMay 11, 2023 Sale$30.247,925239,652554,448May 12, 2023, 04:05 PM
Chivukula PadChief Scientific Officer & COOMay 10, 2023 Sale$30.0017,075512,250562,373May 12, 2023, 04:05 PM
Chivukula PadChief Scientific Officer & COOMay 01, 2023 Sale$25.935,000129,650579,448May 03, 2023, 04:08 PM
Kummerfeld Keith CSee RemarksApr 18, 2023 Option Exercise$8.966,96862,4087,918Apr 19, 2023, 04:57 PM
Kummerfeld Keith CSee RemarksApr 18, 2023 Sale$28.186,968196,358950Apr 19, 2023, 04:57 PM
Chivukula PadChief Scientific Officer & COOApr 03, 2023 Sale$25.385,000126,900584,448Apr 05, 2023, 08:47 PM
Chivukula PadChief Scientific Officer & COOMar 06, 2023 Sale$16.075,00080,350589,448Mar 08, 2023, 09:34 PM
Marquet MagdaDirectorDec 15, 2022 Buy$18.002,22239,99624,942Dec 19, 2022, 05:02 PM
Payne Joseph EPresident and CEONov 23, 2022 Buy$16.515,00082,5501,480,097Nov 28, 2022, 04:07 PM
SASSINE ANDYChief Financial OfficerAug 15, 2022 Option Exercise$18.421,06819,672269,303Aug 17, 2022, 04:05 PM
Chivukula PadChief Scientific Officer & COOJan 04, 2022 Sale$40.008,100324,000594,448Jan 06, 2022, 04:01 PM
Chivukula PadChief Scientific Officer & COODec 16, 2021 Sale$40.003,633145,328602,548Dec 20, 2021, 04:01 PM
Chivukula PadChief Scientific Officer & COODec 08, 2021 Sale$40.006,367254,680606,181Dec 10, 2021, 04:01 PM
Chivukula PadChief Scientific Officer & COONov 01, 2021 Sale$44.4110,000444,100612,548Nov 03, 2021, 11:20 AM
Chivukula PadChief Scientific Officer & COOOct 01, 2021 Sale$44.3610,000443,600622,548Oct 04, 2021, 05:01 PM
Chivukula PadChief Scientific Officer & COOSep 01, 2021 Sale$55.8610,000558,600632,548Sep 02, 2021, 09:06 PM
Ultragenyx Pharmaceutical Inc.DirectorAug 11, 2021 Sale$45.8375,0003,437,2501,400,000Aug 12, 2021, 05:11 PM
Ultragenyx Pharmaceutical Inc.DirectorAug 10, 2021 Sale$55.44725,00040,193,9991,475,000Aug 12, 2021, 05:11 PM
Chivukula PadChief Scientific Officer & COOAug 03, 2021 Sale$40.0710,000400,700642,548Aug 05, 2021, 04:32 PM
Chivukula PadChief Scientific Officer & COOMar 01, 2021 Sale$54.2310,000542,300662,548Mar 03, 2021, 04:30 PM
Chivukula PadChief Scientific Officer & COOFeb 01, 2021 Sale$75.3110,000753,100672,548Feb 03, 2021, 04:45 PM
Chivukula PadChief Scientific Officer & COOJan 04, 2021 Sale$46.4010,000464,000682,548Jan 05, 2021, 06:19 PM
Ultragenyx Pharmaceutical Inc.DirectorDec 09, 2020 Sale$94.97357,74533,975,0432,200,000Dec 10, 2020, 04:55 PM
Ultragenyx Pharmaceutical Inc.DirectorDec 08, 2020 Sale$105.54442,25546,675,5932,557,745Dec 10, 2020, 04:55 PM
Chivukula PadChief Scientific Officer & COODec 01, 2020 Sale$96.1910,000961,900692,548Dec 03, 2020, 05:45 PM
Chivukula PadChief Scientific Officer & COONov 02, 2020 Sale$55.2810,000552,800702,548Nov 03, 2020, 08:01 PM
Chivukula PadChief Scientific Officer & COOOct 01, 2020 Sale$42.8310,000428,300712,548Oct 02, 2020, 05:00 PM
Chivukula PadChief Scientific Officer & COOSep 03, 2020 Sale$45.1610,000451,600722,548Sep 04, 2020, 05:05 PM
Kummerfeld Keith CSee RemarksJun 12, 2020 Buy$33.3345014,999950Jun 12, 2020, 06:22 PM
Payne Joseph EPresident and CEOJun 10, 2020 Buy$31.691,00031,6901,475,097Jun 10, 2020, 09:59 PM
SASSINE ANDYChief Financial OfficerJun 10, 2020 Buy$29.745,000148,700273,245Jun 10, 2020, 09:59 PM
Ultragenyx Pharmaceutical Inc.DirectorMay 20, 2020 Option Exercise$16.00600,0009,600,0003,000,000May 22, 2020, 01:41 PM
SASSINE ANDYChief Financial OfficerDec 05, 2019 Buy$9.735,64954,965268,245Dec 09, 2019, 09:45 PM
SASSINE ANDYChief Financial OfficerDec 03, 2019 Buy$10.0010,000100,000257,596Dec 05, 2019, 09:39 PM
Marquet MagdaDirectorSep 13, 2019 Buy$10.582,30024,33422,720Sep 17, 2019, 09:37 PM
Kummerfeld Keith CSee RemarksSep 12, 2019 Buy$10.695005,347500Sep 12, 2019, 09:00 PM
Payne Joseph EPresident and CEOAug 29, 2019 Buy$11.225,00056,1001,474,097Aug 30, 2019, 05:00 PM
SASSINE ANDYChief Financial OfficerAug 23, 2019 Buy$10.9010,000109,000247,596Aug 26, 2019, 07:00 AM
FARRELL PETER CDirectorAug 20, 2019 Buy$10.854,43248,08742,955Aug 21, 2019, 07:51 PM
FARRELL PETER CDirectorAug 19, 2019 Buy$11.024,68151,58538,523Aug 21, 2019, 07:51 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Chivukula PadChief Scientific Officer & COO03/25/2024610,574
Chivukula PadChief Scientific Officer & COO03/19/2024299,839
Chivukula PadChief Scientific Officer & COO11/01/202393,602
Chivukula PadChief Scientific Officer & COO10/02/2023128,062
Chivukula PadChief Scientific Officer & COO09/01/2023157,263
SASSINE ANDYChief Financial Officer08/15/202321,248
Chivukula PadChief Scientific Officer & COO08/01/2023174,550
Chivukula PadChief Scientific Officer & COO07/14/2023875,250
Kummerfeld Keith CSee Remarks07/14/202362,408
Kummerfeld Keith CSee Remarks07/14/2023243,880
Chivukula PadChief Scientific Officer & COO07/03/2023143,750
Chivukula PadChief Scientific Officer & COO06/01/2023135,800
Chivukula PadChief Scientific Officer & COO05/11/2023239,652
Chivukula PadChief Scientific Officer & COO05/10/2023512,250
Chivukula PadChief Scientific Officer & COO05/01/2023129,650
Kummerfeld Keith CSee Remarks04/18/202362,408
Kummerfeld Keith CSee Remarks04/18/2023196,358
Chivukula PadChief Scientific Officer & COO04/03/2023126,900
Chivukula PadChief Scientific Officer & COO03/06/202380,350
Marquet MagdaDirector12/15/202239,996
Payne Joseph EPresident and CEO11/23/202282,550
SASSINE ANDYChief Financial Officer08/15/202219,672
Chivukula PadChief Scientific Officer & COO01/04/2022324,000
Chivukula PadChief Scientific Officer & COO12/16/2021145,328
Chivukula PadChief Scientific Officer & COO12/08/2021254,680
Chivukula PadChief Scientific Officer & COO11/01/2021444,100
Chivukula PadChief Scientific Officer & COO10/01/2021443,600
Chivukula PadChief Scientific Officer & COO09/01/2021558,600
Ultragenyx Pharmaceutical Inc.Director08/11/20213,437,250
Ultragenyx Pharmaceutical Inc.Director08/10/202140,193,999
Chivukula PadChief Scientific Officer & COO08/03/2021400,700
Chivukula PadChief Scientific Officer & COO03/01/2021542,300
Chivukula PadChief Scientific Officer & COO02/01/2021753,100
Chivukula PadChief Scientific Officer & COO01/04/2021464,000
Ultragenyx Pharmaceutical Inc.Director12/09/202033,975,043
Ultragenyx Pharmaceutical Inc.Director12/08/202046,675,593
Chivukula PadChief Scientific Officer & COO12/01/2020961,900
Chivukula PadChief Scientific Officer & COO11/02/2020552,800
Chivukula PadChief Scientific Officer & COO10/01/2020428,300
Chivukula PadChief Scientific Officer & COO09/03/2020451,600
Kummerfeld Keith CSee Remarks06/12/202014,999
Payne Joseph EPresident and CEO06/10/202031,690
SASSINE ANDYChief Financial Officer06/10/2020148,700
Ultragenyx Pharmaceutical Inc.Director05/20/20209,600,000
SASSINE ANDYChief Financial Officer12/05/201954,965
SASSINE ANDYChief Financial Officer12/03/2019100,000
Marquet MagdaDirector09/13/201924,334
Kummerfeld Keith CSee Remarks09/12/20195,347
Payne Joseph EPresident and CEO08/29/201956,100
SASSINE ANDYChief Financial Officer08/23/2019109,000
FARRELL PETER CDirector08/20/201948,087
FARRELL PETER CDirector08/19/201951,585
Load More Insider Transactions
FUNDS WITH A POSITION IN ARCTURUS THERAPEUTICS HOLDINGS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BLACKROCK INC.2,743,0020.00216%14.37%Other
ARK INVESTMENT MANAGEMENT LLC1,689,6490.4%-17.48%Growth
GEODE CAPITAL MANAGEMENT, LLC550,2630.00172%2.23%Other
ADAGE CAPITAL PARTNERS GP, L.L.C.450,0000.03%NewOther
AQR CAPITAL MANAGEMENT LLC74,2250.00427%-53.57%Other
ROYCE & ASSOCIATES LP131,7180.04%1.45%Value
D. E. SHAW & CO., INC.10,3550.0003%-85.97%Other
ALPS ADVISORS INC28,0130.0067%-0.73%Other
RENAISSANCE TECHNOLOGIES LLC10,2020.0005%ExitedOther
CHANGE IN SHARES OUTSTANDING FOR ARCTURUS THERAPEUTICS HOLDINGS INC
STOCK BUYBACKS FOR ARCTURUS THERAPEUTICS HOLDINGS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
0.98%
1Q
12/31/2023
06/30/2023
1.02%
2Q
12/31/2023
03/31/2023
-1.16%
3Q
12/31/2023
12/31/2022
-7.79%
4Q
12/31/2023
09/30/2022
1.39%
5Q
12/31/2023
06/30/2022
1.55%
6Q
12/31/2023
03/31/2022
1.74%
7Q
12/31/2023
12/31/2021
1.79%
8Q
12/31/2023
09/30/2021
1.89%
9Q
12/31/2023
06/30/2021
1.95%
10Q
12/31/2023
03/31/2021
2.26%
11Q
12/31/2023
12/31/2020
32.16%
12Q
12/31/2023
09/30/2020
16.99%
13Q
12/31/2023
06/30/2020
42.78%
14Q
12/31/2023
03/31/2020
84.80%
15Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
0.98%
1Q
06/30/2023
1.02%
2Q
03/31/2023
-1.16%
3Q
12/31/2022
-7.79%
4Q
09/30/2022
1.39%
5Q
06/30/2022
1.55%
6Q
03/31/2022
1.74%
7Q
12/31/2021
1.79%
8Q
09/30/2021
1.89%
9Q
06/30/2021
1.95%
10Q
03/31/2021
2.26%
11Q
12/31/2020
32.16%
12Q
09/30/2020
16.99%
13Q
06/30/2020
42.78%
14Q
03/31/2020
84.80%
15Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ARCTURUS THERAPEUTICS HOLDINGS INC
LOADING...